Aiforia Technologies Oyj Positioned as Pathology AI Leader

Finnish company Aiforia Technologies Oyj has been rated a "BUY" by NuWays AG, with a target price of EUR 3.50 for the next 12 months. The company, leveraging AI, is expected to revolutionize pathology. As cancer cases rise by 50% until 2040, Aiforia's AI-powered platform aims to bridge the widening gap between demand and the declining number of pathologists.

Aiforia's solutions promise enhanced diagnostic accuracy and efficiency in labs and hospitals. In recent studies, their AI outperformed pathologists in diagnosing certain tumors. Holding over 30% of the European market share, Aiforia has a unique competitive edge, with regulatory approval for half its models.

The global shift towards digital pathology will further accelerate Aiforia’s growth. The company projects a 52% CAGR through 2029, driven by increased demand and slide processing. This structural growth is coupled with strong profitability projections, with EBIT margins anticipated at 27-32%.